Albayrak, YakupHashimoto, Kenji2022-05-112022-05-1120131738-36841976-3026https://doi.org/10.4306/pi.2013.10.4.417https://hdl.handle.net/20.500.11776/9040Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.en10.4306/pi.2013.10.4.417info:eu-repo/semantics/openAccessSigma receptorFluvoxamineAkathisiaDyskinesiaInduced Movement-DisordersNeuropsychiatric DisordersReceptor LigandsTomographyChaperoneDopamineStressBrainDrugsArticle104417420Q3WOS:0003295999000152-s2.0-8489255017224474992Q2